---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-006382"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T05:05:52.174380+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics terminates Chief R&D Officer Cavanagh; separation payment of $341,000

## Summary
- William Cavanagh III departed as Chief R&D Officer effective Feb 7, 2023; Separation Agreement effective Mar 10, 2023.
- Cavanagh receives $341,000 (12 months base salary) paid biweekly, plus health premium equivalent for one year.
- Separation includes full release of claims against the company and confidentiality/non-disparagement obligations.
- Stock options: unvested options terminate; vested options expire 90 days from Feb 7, 2023.
- Agreement includes 45-day consideration period and 7-day revocation period under ADEA.

## SEC filing metadata
- accession: 0001437749-23-006382
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/0001437749-23-006382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/isr20230309_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-006382
- JSON: https://secwatch.observer/filing/0001437749-23-006382.json
- Plain text: https://secwatch.observer/filing/0001437749-23-006382.txt

## Key facts
- Executive change
  William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Research and Development Officer
  source text: In connection with the termination of William Cavanagh III from his position of Chief Research and Development Officer of Perspective Therapeutics, Inc. (the “ Company ”), as previously disclosed on the Form 8-K filed by the Company on February 10, 2023, the Company, Isoray Medical, Inc. (a wholly-owned subsidiary of the Company), and Mr. Cavanagh entered into a Separation Agreement effective March 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/0001437749-23-006382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.